Download presentation
Presentation is loading. Please wait.
Published byFranco Spada Modified over 6 years ago
1
What's on the Horizon? Assessing New First-Line Paradigms for AML Patients Ineligible for Intensive Chemotherapy
3
Treatment Options for AML Patients Ineligible for Intensive CT
4
NCCN Clinical Practice Guidelines: AML
5
AML Patients Ineligible for Intensive CT: Challenges of Traditional Therapy
6
Venetoclax Mechanism of Action
7
Availability of Venetoclax
8
Venetoclax + HMAs in Elderly Patients With Untreated AML: Study Design
9
Venetoclax + HMAs in Elderly Patients With Untreated AML: Responses
10
Venetoclax + HMAs in Elderly Patients With Untreated AML: Serious AEs
11
Assessing Fitness and Making Treatment Decisions
12
Phase 1/2 Study of Venetoclax with LDAC in Treatment-Naive, Elderly Patients with AML Unfit for Intensive CT: 1-Year Outcomes
13
Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with AML Unfit for Intensive CT: 1-Year Outcomes (cont)
14
Glasdegib + LDAC vs AZA or DEC Among AML Patients Ineligible to Receive Intensive CT
15
Glasdegib Mechanism of Action
16
Glasdegib + LDAC vs AZA or DEC Among AML Patients Ineligible to Receive Intensive CT: CR Results
17
Glasdegib: Potential Role in AML Treatment
18
Resurgence of Nontargeted Therapy for AML Treatment
19
Gemtuzumab Ozogamicin vs BSC In Older Patients With AML Unsuitable for Intensive CT: EORTC-GIMEMA AML-19 Trial
20
Gemtuzumab Ozogamicin vs BSC In Older Patients With AML Unsuitable for Intensive CT: EORTC-GIMEMA AML-19 Trial
21
Gemtuzumab Ozogamicin: Potential Role in AML Treatment
22
IDH Inhibitors In AML
23
Availability of IDH Inhibitors
24
Ivosidenib In Patients with IDH1-Mutant Untreated AML: Results From a Phase 1 Dose Escalation and Expansion Study
25
Unanswered Questions for Treating AML Patients Ineligible for Intensive CT
26
Venetoclax + HMAs in Elderly Patients With Untreated AML: Responses
27
FLT3 Inhibitors In AML
28
Phase 3 Study of Quizartinib vs SOC in FLT3-ITD R-R AML: QUANTUM-R
29
Gilteritinib In Newly Diagnosed FLT3 Mutated AML Patients Ineligible for Intensive Induction CT: Data From Safety Cohort
30
Mutational Co-Occurrence in AML
31
FLT3 Inhibitors: Potential Role in AML Treatment
32
Fit vs Unfit: How Do You Decide?
33
Need For Assessments of Fitness In the Future?
34
Evaluating MRD In AML
35
High MRD-Negative Rates Seen with Venetoclax in Patients With AML
36
Conclusions
37
Abbreviations
38
Abbreviations (cont)
39
Abbreviations (cont)
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.